The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition

Saved in:
Bibliographic Details
Published inAmyloid Vol. 26; no. sup1; pp. 39 - 40
Main Authors Wixner, Jonas, Westermark, Per, Ihse, Elisabet, Pilebro, Björn, Lundgren, Hans-Erik, Anan, Intissar
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 2019
Subjects
Adult
Aged
Aged, 80 and over
Amyloid - drug effects
Amyloid Neuropathies, Familial - drug therapy
Amyloid Neuropathies, Familial - genetics
Amyloid Neuropathies, Familial - pathology
Diflunisal - administration & dosage
Diflunisal - adverse effects
Drug-Related Side Effects and Adverse Reactions - classification
Drug-Related Side Effects and Adverse Reactions - pathology
Female
Humans
Male
Middle Aged
Mutation
Prealbumin - genetics
Sweden - epidemiology
Sweden
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ISSN:1350-6129
1744-2818
1744-2818
DOI:10.1080/13506129.2019.1593133